-
Product Insights
Likelihood of Approval Analysis for Primary Immune Deficiency (PID)
Overview How likely is it that the drugs in Primary Immune Deficiency (PID) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Primary Immune Deficiency (PID) Overview Primary immune deficiency (PID) is...
-
Product Insights
Likelihood of Approval Analysis for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
Overview How likely is it that the drugs in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview Idiopathic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Immune Globulin (Human) in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Immune Globulin (Human) in Epilepsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Immune Globulin (Human) in Epilepsy Drug Details: Human immunoglobulin (Privigen /...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Immune Globulin (Human) in Tachycardia (Tachyarrhythmias)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Immune Globulin (Human) in Tachycardia (Tachyarrhythmias) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Immune Globulin (Human) in Tachycardia (Tachyarrhythmias) Drug Details: Human Immunoglobulin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Hyaluronidase (Recombinant, Human) + Immune Globulin (Human)) in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Hyaluronidase (Recombinant, Human) + Immune Globulin (Human)) in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Hyaluronidase (Recombinant, Human) + Immune Globulin...
-
Product Insights
NewPrimary Immune Deficiency (PID) – Drugs In Development, 2024
Empower your strategies with our Primary Immune Deficiency (PID) – Drugs In Development, 2024 report and make more profitable business decisions. Primary immune deficiency (PID) is defined as weakened immune system, allowing repeated infections and other health problems to occur more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, and digestive problems such as cramping, loss of appetite, nausea, and diarrhea. The Primary Immune Deficiency (PID) drugs in development market research report...
-
Product Insights
NewSevere Combined Immune Deficiency (SCID) – Drugs In Development, 2024
Empower your strategies with our Severe Combined Immune Deficiency (SCID) – Drugs In Development, 2024 report and make more profitable business decisions. Severe combined immunodeficiency (SCID) is a group of rare disorders caused by mutations in different genes involved in the development and function of infection-fighting immune cells. Infants with SCID appear healthy at birth but are highly susceptible to severe infections. The condition is fatal, usually within the first year or two of life, unless infants receive immune-restoring treatments such...
-
Product Insights
NewIdiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Drugs In Development, 2024
Empower your strategies with our Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Drugs In Development, 2024 report and make more profitable business decisions. Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from nose, and superficial bleeding into skin that appears as a rash of pinpoint sized reddish purple spots, usually on the lower legs. The Idiopathic Thrombocytopenic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Immune Globulin (Human) in Neuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Immune Globulin (Human) in Neuropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Immune Globulin (Human) in Neuropathy Drug Details: Human normal immunoglobulin (Octagam, ...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RAY-121 in Autoimmune Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RAY-121 in Autoimmune Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RAY-121 in Autoimmune Disorders Drug Details: RAY-121 is under development for...